AbCellera Biologics (ABCL) Consolidated Net Income: 2020-2023
Historic Consolidated Net Income for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$47.1 million.
- AbCellera Biologics' Consolidated Net Income fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- Per AbCellera Biologics' latest filing, its Consolidated Net Income stood at -$47.1 million for Q4 2023, which was down 64.80% from -$28.6 million recorded in Q3 2023.
- AbCellera Biologics' Consolidated Net Income's 5-year high stood at $168.6 million during Q1 2022, with a 5-year trough of -$47.1 million in Q4 2023.
- Its 3-year average for Consolidated Net Income is $13.8 million, with a median of -$14.1 million in 2021.
- Data for AbCellera Biologics' Consolidated Net Income shows a peak YoY increase of 5,700.62% (in 2021) and a maximum YoY decrease of 693.91% (in 2021) over the last 5 years.
- Over the past 4 years, AbCellera Biologics' Consolidated Net Income (Quarterly) stood at $161.2 million in 2020, then plummeted by 62.80% to $59.9 million in 2021, then plummeted by 149.86% to -$29.9 million in 2022, then slumped by 57.73% to -$47.1 million in 2023.
- Its Consolidated Net Income was -$47.1 million in Q4 2023, compared to -$28.6 million in Q3 2023 and -$30.5 million in Q2 2023.